Loading clinical trials...

A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase I, Open Label, Dose Escalation Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

NCT01068977•Genentech, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase I, open label, dose-escalation study of MetMAb administered by intravenous (IV) infusion in patients with advanced solid malignancies that are refractory to or for which there is no standard of care. The study consists of a dose-escalation stage, an expansion stage testing MetMAb at the recommended Phase II dose (RP2D), and a dose-escalation stage testing the combination of MetMAb, at two different doses with bevacizumab at a recommended dose.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologic documentation of incurable, locally advanced, or metastatic solid malignancy that has failed to respond to at least one prior regimen or for which there is no standard therapy
•Disease that is measurable or evaluable by Response Evaluation Criteria In Solid Tumors (RECIST)
•Life expectancy ≥12 weeks

Exclusion Criteria

•Less than 4 weeks since the last anti-tumor therapy
•Patients receiving erythropoietin products
•Active infection requiring antibiotics
•Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs
•Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
•Clinically important history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
•Known human immunodeficiency virus infection
•Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases

Key Dates

Start Date

August 1, 2007

Primary Completion Date

January 1, 2010

Completion Date

January 1, 2010

Last Updated

May 19, 2017

Enrollment

ACTUAL participants

Conditions

Solid Cancers

Interventions

bevacizumab

DRUG

MetMAb

DRUG

MetMAb

DRUG

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842

Advanced Solid Cancers

View study

RECRUITINGNA

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

NCT03514368

Solid Cancers

View study

RECRUITINGPHASE1/PHASE2

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 19, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria

Exclusion Criteria

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.

Real-life Performance Evaluation of the LiFlow X-ray Platform

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers